Neonatal screening and long-term follow-up of phenylketonuria: the French database

V Abadie1, J Berthelot, F Feillet

  • 1Service de Pédiatrie Générale, Hôpital Necker-Enfants Malades, Paris, France.

Early Human Development
|October 20, 2001
PubMed

Insights

Phenylketonuria (PKU) screening in France has been effective since 1966, demonstrating a stable incidence and improved patient outcomes. Early diagnosis and dietary management are crucial for successful long-term results in PKU patients.

Area of Science:

  • Medical screening programs
  • Pediatric metabolic disorders
  • Public health initiatives

Background:

  • Neonatal screening for phenylketonuria (PKU) initiated in France in 1966.
  • A national association established in 1978 to manage the screening program and patient follow-up.

Purpose of the Study:

  • Evaluate the French PKU screening program's effectiveness.
  • Assess hyperphenylalaninaemia epidemiology, screening efficacy, patient management, and outcomes.

Main Methods:

  • Utilized a national database compiled from physician questionnaires and a 1994 inquiry.
  • Investigated diagnosis, treatment, and school outcomes for all French PKU patients.

Main Results:

  • PKU diagnosed in 81.6% of hyperphenylalaninaemia (HPA) cases; incidence stable at 1:17,124 births since 1980.
  • Screening sensitivity reached 99.3%; median age at diet initiation decreased to 14 days by 1996.
  • Diet discontinuation age increased from 6 years (pre-1990) to 8-10 years, correlating with better school outcomes.

Conclusions:

  • Nationwide organized screening programs are beneficial for PKU management.
  • Early neonatal diagnosis and timely diet initiation are vital for PKU patients.
  • Extended strict dietary adherence in childhood improves patient outcomes.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...